Leveraging the GLP-1 boom, VITL secured $7.5 million to overhaul cash-pay clinic prescriptions

The number of medical spas, weight-loss clinics and concierge practices where patients pay membership fees to have direct access to doctors often on the same day has increased in recent years. But while patients pay for these services out of pocket, providers often still rely on programs designed for traditional insurance-based care.

VITL, an 18-month-old startup, claims to be solving one of the biggest technology bottlenecks in the sector by building an e-prescribing platform – a digital tool for sending and managing prescriptions – designed specifically for cash-paying medical businesses.

VITL on Wednesday announced a $7.5 million Series A funding round led by SignalFire.

Founder and CEO Charlie Jordan built the Nashville-based company after realizing how much time medical providers spent managing prescriptions for treatments not covered by insurance.

Many providers still rely on faxes or phone calls to send prescriptions to compounding pharmacies, which create custom medications to order, often without knowing the final cost to the patient or how long the order will take. The VITL platform fixes this problem by connecting clinics to a nationwide network of compounding pharmacies, offering real-time price comparisons and Amazon-style order tracking.

“We shortened the prescription time from several minutes to a few seconds,” Jordan told TechCrunch.

For clinics that field dozens of orders each day, the time savings add up.

VITL estimates that its technology saves customers up to two full business days per month by automating a cumbersome and opaque process.

Cash payment providers clearly see the value in the VITL platform. Just over a year after launch, the company reports onboarding more than 630 clinics and has achieved annual recurring revenue (ARR) in the eight figures, meaning the company is on track to generate at least $10 million annually.

However, the 630 clients represent just a small portion of a market that includes tens of thousands of clinics across the United States. With growing interest in GLP-1s – a class of drugs that includes Ozempic and Wegovy – peptides, and aesthetic procedures such as Botox, the number of cash-driven healthcare companies is set to expand.

VITL never took SignalFire public, but the startup’s rapid growth caught its attention. This interest has translated into a new $7.5 million Series A led by the venture firm, which is known for using data and artificial intelligence to identify startups.

VITL competes in part with Surescripts, a leader in electronic prescriptions, and with specialty clinic platforms such as Jane Software, which bundles prescription features into broader electronic health record (EHR) software. What sets VITL apart from these competitors, she says, is its sole focus on the workflow requirements of the cash-paying medical sector.